临床试验安全数据综合分析的估计框架和统计考虑
Katarina Hedman1, George Kordzakhia2, Hongjian Li2
1Biometrics, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. katarina.hedman@astrazeneca.com.
药物开发中的综合安全分析提高了准确性和患者保护. 应用ICH估计和框架通过澄清组合数据的临床问题和统计方法来确保可解释的结果.
科学领域:
- 临床药理学 临床药理学
- 生物统计学 生物统计学
- 药物开发 药物开发
背景情况:
- 安全性分析在药物开发中对于患者保护至关重要.
- 单个研究往往缺乏准确评估安全事件的样本大小.
- 综合分析 (聚合或元分析) 提高了准确性,但需要结构化的工作流程.
研究的目的:
- 将ICH估计和框架应用于综合临床试验分析.
- 总结用于可解释的综合安全分析的关键统计假设.
主要方法:
- 在临床试验整合中应用ICH估计和框架.
- 制定规划综合安全分析的原则.
- 专注于包含/排除标准和信号检测集成.
主要成果:
- 估计和框架有助于理解综合安全分析规划的关键统计方面.
- 原则涉及临床问题,估计和估计.
- 该框架为研究包含/排除和信号检测提供了明确的标准.
结论:
- 执行综合安全分析需要了解临床问题和估计.
- 谨慎的规划和健全的统计实践对于避免偏见至关重要.
- 估计和框架对于有效性和安全性评估,包括综合分析都是有价值的.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Statistical Software for Data Analysis and Clinical Trials
Hazard Ratio
For example, in a clinical trial...
Comparing the Survival Analysis of Two or More Groups
Assumptions of Survival Analysis
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
